J-AXEL: nab-paclitaxel at least equal to docetaxel in pretreated NSCLC
J-AXEL: nab-paclitaxel at least equal to docetax
Nivolumab as a new option in patients with relapsed malignant mesothelioma
Nivolumab as a new option in patients with relap
Interview: Lung cancer screening: hurdles in daily routine and in the research laboratory
Interview: Lung cancer screening: hurdles in daily rou
Immunotherapy: combination regimens and new data on the significance of mutations
Immunotherapy: combination regimens and new data
What is new in SCLC?
What is new in SCLC? Lurbinectedin plus irin
Interview: Antibody-drug conjugates: the age of almost unlimited possibilities has just begun
Interview: Antibody-drug conjugates: the age of
Specific treatment approaches in the EGFR-mutated setting
Specific treatment approaches in the EGFR-mutate
KRAS, HER2 & ALK: targeted options and sequencing issues
KRAS, HER2 & ALK: targeted options and seque
Pushing the bounds in early-stage lung cancer
Pushing the bounds in early-stage lung cancer
PD-1 inhibition and (Non-)Hodgkin lymphoma: promising outcomes in an emerging field
PD-1 inhibition and (Non-)Hodgkin lymphoma: prom
